Latest News
From the Journals
Novel agent to be studied in relapsed/refractory AML
The phase 1b/2 trial will study a polo-like kinase 1 inhibitor.
From the Journals
Start with fitness when deciding on treatment for elderly AML patients
In this difficult-to-treat population, fitness assessments help.
From the Journals
Cyclophosphamide after transplant reduced GVHD in myeloma patients
Anticancer agents may be more active after transplantation than before, researchers suggested.
News
MACRA Monday: Elder maltreatment screening
Screen an elderly patient for maltreatment and document a follow-up plan, if appropriate, and you could avoid a 4% MIPS penalty.
From the Journals
Squamous cell carcinoma linked to 25% increase in all-cause mortality
Patients with SCC “may need additional education and age-appropriate screening to prevent deaths from major diseases,” the authors concluded.
Conference Coverage
Studies need to address best follow-on therapy to ibrutinib in CLL
There was no clear standard treatment approach for patients with CLL who discontinued ibrutinib or for whom ibrutinib did not work, in a...
News
FDA approves first-in-class drug for hemophilia A with Factor VIII
The new treatment is given as a weekly injection.
Conference Coverage
Universal paternal Rh screening is cost effective in IVF
SAN ANTONIO – The strategy would save more than $1 million per 100,000 Rh negative pregnancies, if done in IVF populations.
News
FDA approves obinutuzumab for follicular lymphoma
Approval is based on a 28% lower risk of disease progression or death after 2 years for patients on the obinutuzumab-based regimen.
Conference Coverage
Restrictive transfusion strategy safe in cardiac surgery
ANAHEIM, CALIF. – Using a lower hemoglobin threshold for transfusion in surgery with cardiopulmonary bypass is as safe as the usual 9.5 g/dL.
News
FDA authorizes next-generation sequencing test for tumor profiling
MSK-IMPACT is a custom targeted sequencing platform that uses exon capture and sequencing to identify point mutations, small insertions and...